October 30, 2025
Frederick, MD – Jecho Laboratories, Inc. will present emerging clinical data from a Phase 1 study of JL18008, an innovative IL-7/HSA fusion protein for HIV immunological non-responders and lymphocytopenia, at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting.
The SITC meeting will be held November 5 – 9, 2025 in National Harbor, Maryland.
Details on the presentation are below:
Abstract 1339: A randomized, double-blind, placebo-controlled, dose-escalated, first-in-human study to assess the safety, tolerability, and T cell replenishment of JL18008, a long-acting IL-7, in healthy subjects
- Abstract Presentation Number: 1339
- Session Time: Friday, November 7, 2025 viewing 10 a.m. – 7 p.m. EST
- Location: Gaylord National Resort & Convention Center – Exhibit Halls AB
- SITC link: TBD